Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 19907075)

1.

PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice.

Valenzuela JO, Iclozan C, Hossain MS, Prlic M, Hopewell E, Bronk CC, Wang J, Celis E, Engelman RW, Blazar BR, Bevan MJ, Waller EK, Yu XZ, Beg AA.

J Clin Invest. 2009 Dec;119(12):3774-86. doi: 10.1172/JCI39692. Epub 2009 Nov 9.

2.

Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice.

Haarberg KM, Li J, Heinrichs J, Wang D, Liu C, Bronk CC, Kaosaard K, Owyang AM, Holland S, Masuda E, Tso K, Blazar BR, Anasetti C, Beg AA, Yu XZ.

Blood. 2013 Oct 3;122(14):2500-11. doi: 10.1182/blood-2012-12-471938. Epub 2013 Aug 1.

3.

IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.

Teshima T, Hill GR, Pan L, Brinson YS, van den Brink MR, Cooke KR, Ferrara JL.

J Clin Invest. 1999 Aug;104(3):317-25.

5.

Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.

Giver CR, Montes RO, Mittelstaedt S, Li JM, Jaye DL, Lonial S, Boyer MW, Waller EK.

Biol Blood Marrow Transplant. 2003 Oct;9(10):616-32.

PMID:
14569558
8.

Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.

Asakura S, Hashimoto D, Takashima S, Sugiyama H, Maeda Y, Akashi K, Tanimoto M, Teshima T.

J Clin Invest. 2010 Jul;120(7):2370-8. doi: 10.1172/JCI39165. Epub 2010 Jun 7.

10.
11.

Promoting regulation via the inhibition of DNAM-1 after transplantation.

Koyama M, Kuns RD, Olver SD, Lineburg KE, Lor M, Teal BE, Raffelt NC, Leveque L, Chan CJ, Robb RJ, Markey KA, Alexander KA, Varelias A, Clouston AD, Smyth MJ, MacDonald KP, Hill GR.

Blood. 2013 Apr 25;121(17):3511-20. doi: 10.1182/blood-2012-07-444026. Epub 2013 Feb 21.

12.

Type I-IFNs control GVHD and GVL responses after transplantation.

Robb RJ, Kreijveld E, Kuns RD, Wilson YA, Olver SD, Don AL, Raffelt NC, De Weerd NA, Lineburg KE, Varelias A, Markey KA, Koyama M, Clouston AD, Hertzog PJ, Macdonald KP, Hill GR.

Blood. 2011 Sep 22;118(12):3399-409. doi: 10.1182/blood-2010-12-325746. Epub 2011 Jun 30.

13.

Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.

Zeis M, Uharek L, Hartung G, Glass B, Steinmann J, Schmitz N.

Hematol J. 2001;2(2):136-44.

PMID:
11424006
15.

Elimination of leukemia in the absence of lethal graft-versus-host disease after allogenic bone marrow transplantation.

Drobyski WR, Gendelman M, Vodanovic-Jankovic S, Gorski J.

J Immunol. 2003 Mar 15;170(6):3046-53.

18.

A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses.

Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL.

Nat Med. 2005 Nov;11(11):1244-9. Epub 2005 Oct 16.

PMID:
16227991
19.

Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects.

Reddy P, Teshima T, Hildebrandt G, Williams DL, Liu C, Cooke KR, Ferrara JL.

Blood. 2003 Apr 1;101(7):2877-85. Epub 2002 Nov 14.

20.

CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.

Matte-Martone C, Liu J, Jain D, McNiff J, Shlomchik WD.

Blood. 2008 Apr 1;111(7):3884-92. doi: 10.1182/blood-2007-11-125294. Epub 2008 Jan 25.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk